(CLPT) ClearPoint Neuro, Inc. Business Model Canvas Research

Koninklijke Philips N.V. is a core MRI partner for ClearPoint Neuro, and the workflow depends on MRI compatibility at 1.5T and 3T. Pairing ClearPoint Neuro with a global imaging leader helps tighten suite integration, speed procedure setup, and support more efficient MRI-guided neurosurgery.

• MRI fit is central to workflow
• 1.5T and 3T scanner use
• Better suite integration and speed

Blackrock Neurotech and CLS Americas extend ClearPoint Neuro’s ecosystem beyond navigation, adding neurotechnology and laser-therapy capabilities for more complex brain interventions. These partnerships support device integration and therapy delivery workflows, though ClearPoint has not disclosed partnership-specific revenue or 2025/2026 financial terms.

• Broaden neurotechnology reach.
• Support laser-therapy delivery.
• Help complex brain procedures.

ClearPoint Neuro, Inc. runs multiple strategic partnerships and license deals, so partner integration is a core operating task. It has to align software, imaging, and therapy workflows with each partner system while keeping contracts, quality rules, and regulatory duties in sync.

• Coordinates partner tech integration
• Manages licensing and compliance
• Keeps collaborations productive

ClearPoint Neuro, Inc. backs surgeons, hospital staff, and procedure teams after deployment with hands-on clinical training and ongoing support. That matters because its system is used in MRI suite environments, where precise workflow and device handling help protect patient safety and procedure quality.

• Train teams for MRI suite use
• Support safe, effective adoption
• Help maintain procedure consistency

ClearPoint Neuro's edge is clinical and regulatory know-how: it sells into a procedure-driven, FDA-reviewed neurosurgery market where imaging, sterile workflow, and device approval steps shape adoption. The Company reported about $35 million of 2024 revenue, showing this expertise turns technology into real hospital use.

• Imaging and workflow expertise
• Regulatory path knowledge
• Faster hospital adoption

ClearPoint Neuro’s move from MRI Interventions sharpened its identity around neurosurgery and imaging, making the brand easier to trust in a niche market. Named ties with hospitals, imaging teams, and device partners strengthen execution; in FY2025, the company still posted about $35M in revenue, so these relationships matter for repeat use and adoption.

• Focused brand = clearer market signal.

• Partner names add clinical credibility.

• Relationships support commercial traction.

ClearPoint Neuro’s MRI-suite compatibility lets clinicians use the ClearPoint Neuro Navigation System inside the imaging room, so they can keep procedures in the MRI workflow without moving the patient. That lowers handoffs, saves setup time, and supports MRI-guided procedures where real-time imaging matters most.

• Stays in the MRI suite
• Reduces workflow disruption
• Supports real-time imaging

ClearPoint Neuro, Inc. enables controlled intracranial delivery, placing therapies directly in the brain to improve targeting and reduce off-target exposure. This gives physicians precision at the point of treatment, which matters for drugs and other interventions that need exact placement.

• Direct brain delivery
• Better target accuracy
• Point-of-care precision

ClearPoint Neuro’s customer relationship here is built on keeping the installed base working after hospital placement: service, software updates, and technical support make each system harder to replace and more likely to be used again. That support model drives repeat use and platform stickiness, especially in neurosurgery workflows where uptime matters.

• Retains hospitals after installation
• Supports repeat system use
• Raises switching costs over time

ClearPoint Neuro, Inc. builds collaborative clinical relationships with academic centers and research-focused clinicians, which helps turn real procedures into new uses, peer-reviewed evidence, and publications. These ties also build trust in the platform; in FY2025, the company kept scaling this model through its clinical and research network.

• Academic centers drive new applications
• Research clinicians generate evidence
• Publications support adoption
• Trust grows through real-world use

ClearPoint Neuro, Inc. uses neurosurgical meetings and KOLs to reach hospital buyers where evidence matters most. In niche medtech, peer validation can move adoption faster than ads, so conference demos and surgeon advocacy help build trust and clinical awareness.

• Targets neurosurgeons and hospital teams
• KOLs add peer credibility
• Events support product validation

ClearPoint Neuro, Inc. uses its website, product pages, clinical education content, and investor materials to help surgeons, hospitals, and partners find and assess its offerings; these digital channels also support a direct sales model by shortening the path from discovery to sales outreach. They matter for investor visibility too, because the same site hosts filings, earnings updates, and product news.

• Drives product discovery and lead capture
• Supports clinical training and education
• Improves investor and partner communication
• Complements direct sales, not replaces it

Neuro-oncology and biopsy centers use ClearPoint Neuro, Inc. to guide brain biopsy needles with image-based precision, which helps improve targeting in small or hard-to-reach lesions. The segment values minimally invasive access and tighter procedural control, especially when millimeter-level placement matters.

• Image-guided needle targeting
• Minimally invasive biopsy access
• Higher procedural control

Academic and translational groups use ClearPoint Neuro, Inc. tools to test new brain therapies, including drug delivery, infusion, and laser-based procedures. These early users help move ideas into larger studies and future commercial uses, which supports the Company Name’s broader clinical pipeline.

• Studies new brain therapy methods
• Tests delivery, infusion, laser use
• Supports future indication growth

ClearPoint Neuro, Inc. relies on a specialized sales force and clinical support team to drive adoption of complex neurosurgical procedures, so this cost line is tied to procedure growth, training, and in-field case support. Marketing spend is focused on education, conferences, and direct customer outreach, which helps convert clinical interest into active use.

• Sales team drives procedure adoption
• Clinical support helps complex cases
• Marketing funds education and conferences
• Field support reduces workflow friction

ClearPoint Neuro, Inc. keeps general administration lean, but G&A still covers finance, legal, HR, and corporate work that supports the platform. It also carries licensing and partnership fees, which can rise as the Company adds more device, software, and channel agreements. These overhead costs are part of the fixed base that supports day-to-day operations.

• Finance, legal, HR, corporate
• Licensing and partnership costs
• Supports operating scale

ClearPoint Neuro's service and support contracts keep hospitals' systems ready through maintenance, software updates, and technical help, which helps protect uptime and clinical use. The stream is recurring by nature, so it smooths cash flow versus one-time device sales.

• Maintenance and updates
• Technical support
• Predictable recurring revenue

ClearPoint Neuro, Inc. can earn licensing and collaboration revenue through royalties, license fees, and partner payments tied to its institutional and corporate agreements. In FY2025, this stream helped complement product sales and added a higher-margin layer to revenue mix.

• Royalties, license fees, partner payments
• Backed by multiple partnerships
• Supports product-sales growth